Pharmaceutical News

RSS

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Joseph F. Finn, Jr., C.P.A., Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties will be auctioned on May 28, 2010. The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors. He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.

12 Apr 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.

12 Apr 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Meijer adds Metformin Immediate Release to free medication program

With diabetes affecting the lives of millions of people throughout the Midwest, Meijer announced plans today to begin offering Metformin Immediate Release, the most commonly prescribed treatment for type 2 diabetes, at no cost to those with a medical prescription. Meijer's program will include doses prescribed in 500mg, 850mg and 1000mg tablets.

12 Apr 2010

High OOP costs discouraging many cancer patients from filling prescriptions

A new study presented today at the Academy of Managed Care Pharmacy's 22nd Annual Meeting finds that one in six cancer patients with high out-of-pocket (OOP) costs abandons their medication. The study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, found patients with an OOP cost greater than $200 were at least three times more likely to not fill their prescription than those with OOP costs of $100 or less.

12 Apr 2010

Global study shows wide variations in treatment of women with early breast cancer

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

12 Apr 2010

Sun Pharmaceutical Industries' generic Namenda ANDA: USFDA grants tentative approval

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

12 Apr 2010

FDA holds public meeting to obtain comments on PDUFA program

The U.S. Food and Drug Administration will hold a public meeting on April 12, 2010, to obtain comments on the Prescription Drug User Fee Act program. The program authorizes user fees for FDA product reviews, which currently fund more than half of new drug review costs.

12 Apr 2010

Three in ten women use letrozole to treat infertility: Study

About three in ten patients using letrozole (Femara), a common medication for treating breast cancer, are likely taking the medication to treat infertility, according to a new study presented today at the Academy of Managed Care Pharmacy's 22nd Annual Meeting in San Diego by Prime Therapeutics, a thought leader in pharmacy benefit management.

12 Apr 2010

FDA issues complete response letter regarding the NDA for OMAPRO

ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

12 Apr 2010

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

12 Apr 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

Penwest Pharmaceuticals Co. today announced that it has signed a drug development and commercialization agreement with Alvogen, Inc. under which Penwest and Alvogen have agreed to identify and select up to five compounds for generic development. Penwest's TIMERx technology may be used for each compound selected.

9 Apr 2010

More public-private partnerships crucial for success of Italian pharmaceutical industry

The newly retired Chief Executive Officer of Roche Pharmaceuticals Bill Burns today led calls for more public-private partnerships in the pharmaceutical industry at the launch of the Italian Institute of Technology's Drug Discovery and Development Unit (D3).

9 Apr 2010

RED BOOK Drug References continue to provide current pricing, product information on drugs

Some vendors have announced they will stop publishing the Average Wholesale Price of drugs in 2011, but Thomson Reuters will continue to supply this needed information in RED BOOK.

9 Apr 2010

Labopharm: Investment report

StockPreacher.com announces an investment report featuring Labopharm Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Non-psychoactive cannabis to be unveiled at Annual National Clinical Conference on Cannabis Therapeutics

The availability of a new type of medical cannabis strain will be presented for the first time by Steve DeAngelo, who has been featured on CNN, The Wall Street Journal, Fortune Magazine, and The New York Times as Executive Director of one of the nation's top model and non-profit medical cannabis dispensaries, Harborside Health Center in Oakland, California.

9 Apr 2010

Pharmaceutical News

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Meijer adds Metformin Immediate Release to free medication program

High OOP costs discouraging many cancer patients from filling prescriptions

Global study shows wide variations in treatment of women with early breast cancer

Sun Pharmaceutical Industries' generic Namenda ANDA: USFDA grants tentative approval

FDA holds public meeting to obtain comments on PDUFA program

Three in ten women use letrozole to treat infertility: Study

FDA issues complete response letter regarding the NDA for OMAPRO

Resverlogix highlights features of RVX-208 drug at ATVB conference

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

More public-private partnerships crucial for success of Italian pharmaceutical industry

RED BOOK Drug References continue to provide current pricing, product information on drugs

Labopharm: Investment report

Non-psychoactive cannabis to be unveiled at Annual National Clinical Conference on Cannabis Therapeutics

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News